Interstitial Lung Disease and Obstructive Sleep Apnea
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05838183, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Dan Liu
- Trial code
- NCT05838183
- Record updated
- 10 February 2026
- Original description
Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease.Read full original descriptionShow less
Study on the Clinical Characteristics of Interstitial Lung Disease and Obstructive Sleep Apnea
Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease.
All patients undergo polysomnography (PSG) and drug-induced sleep endoscopy(DISE). The biological specimens was obtained for molecular biology or other tests.We detected ZNF331, Claudin1, Claudin2, Claudin3, Claudin4, and IL22 as biomarkers to differentiate the diagnostic efficiency of OSA in ILD, ILD+OSA, OSA, and Ctrl groups, respectively
Inclusion: over 18 years old and under 80 years old; Clinical diagnosis of interstitial lung disease or obstructive respiratory sleep apnea syndrome; Patient is conscious and capable of signing informed consent; The patient may wear a polysomnograph.
Exclusion: malignant tumors; severe heart failure; autoimmune diseases; pulmonary embolism, and end-stage chronic obstructive pulmonary disease; uremia; Patients with mental illnesscannot sign informed consent on their own.